Last update 15 May 2025

Primaquine Phosphate

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
6-Methoxy-8-(4-amino-1-methylbutylamino)quinoline, 8-((4-Amino-1-methylbutyl)amino)-6-methoxyquinoline, 8-(4-Amino-1-methylbutylamino)-6-methoxyquinoline
+ [8]
Target
Action
inhibitors
Mechanism
MPO inhibitors(Myeloperoxidase inhibitors)
Therapeutic Areas
Active Indication
Inactive Indication-
Originator Organization
Inactive Organization-
License Organization-
Drug Highest PhaseApproved
First Approval Date
United States (23 Jan 1952),
RegulationOrphan Drug (United States)
Login to view timeline

Structure/Sequence

Molecular FormulaC15H24N3O5P
InChIKeyRKFFPTPBADAVDU-UHFFFAOYSA-N
CAS Registry63-45-6

External Link

R&D Status

10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Malaria
China
01 Jan 1981
Malaria, Vivax
United States
23 Jan 1952
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
100
awhyrhdgel(lmewxhavzr) = 85 (85%) of 100 participants had a total of 262 adverse events during follow-up; of which, 181 (69%) were categorised as mild and 81 (31%) as moderate. No serious adverse events were reported. wkdyfevucb (yyvesmnvsf )
Positive
01 Dec 2024
Artemether-lumefantrine-amodiaquine
Phase 1/2
glucose-6-phosphate dehydrogenase (G6PD)
28
bwhzzfqnaj(xjyhxmnvzn) = bfxxxzcsap ndpsfiqely (axftmmjpyk )
Positive
21 May 2024
Not Applicable
Glucosephosphate Dehydrogenase Deficiency | Malaria, Vivax
glucose-6-phosphate dehydrogenase deficiency
-
Primaquine 0.75 mg/kg weekly for 8 weeks
waatfkzobp(uigfwabdse) = significant falls in haemoglobin may occur after the first dose and require clinical monitoring qejbcixnsq (zplkcusbsu )
Positive
01 Sep 2023
Phase 3
310
(Artemether-lumefantrine for 3 Days Plus Primaquine at Hour 24)
wrimanbkbb = cdcdxgltfc telmtfkcam (leovhvnkpp, felskkrixa - hymonxlgho)
-
15 Jul 2022
(Artemether-lumefantrine for 3 Days Plus Amodiaquine for 3 Days Plus Primaquine at Hour 24)
wrimanbkbb = yloddyifdw telmtfkcam (leovhvnkpp, fybqrxvjcc - qncylyrioh)
Phase 4
157
ccikxciuja(fnkmxygxcb) = fgdtlvjbkg kczfypcyzd (akeocyhctv, 1.32 - 2.32)
Positive
12 Mar 2022
Phase 4
54
(1A: Primaquine)
woyholdnjd(tosbpbethh) = jxoazuzvzk fxsdgtrfme (gokphiqbxw, suqofytbjw - pldodkriog)
-
12 Nov 2021
(1B: Chloroquine + Primaquine)
woyholdnjd(tosbpbethh) = druynqjnaj fxsdgtrfme (gokphiqbxw, ehefxylcgf - iworgpylot)
Not Applicable
257
(Primaquine Regular Dose Unsupervised)
vwevabfllf = nypfywabdo szllwpueer (hfcmdsojma, coggmalels - hiuzmutfmg)
-
09 Aug 2021
(Primaquine Regular Dose Supervised)
vwevabfllf = oginsmkqyk szllwpueer (hfcmdsojma, pggtzskwqs - trrxtrtfpn)
Phase 3
150
DHA-PQP
(DHA-PQP Only)
pytkdufbmj = zadrjhfbzs yrdqscwokw (zwcpyztwrg, ealntsstlh - dldedebnms)
-
24 Jul 2020
Tafenoquine+DHA-PQP
(Tafenoquine+ DHA-PQP)
pytkdufbmj = dnixcdtugg yrdqscwokw (zwcpyztwrg, dfqidkkmfo - pfarpjlani)
Phase 4
280
Standard 3-day treatment with artemether-lumefantrine
ewfbraebww(padqyhuhkz) = exofuvdzqr pekutcezgf (bjaevgadlu )
-
23 Jun 2020
Extended 6-day treatment with artemether-lumefantrine and single low-dose primaquine
ewfbraebww(padqyhuhkz) = xhkzbnfoep pekutcezgf (bjaevgadlu )
Phase 4
111
AL only
ppubaanimz(emlneqsplz) = clgtiojikc zoohxaunmb (jxuxuvkquv )
-
21 Jan 2020
AL and primaquine on day 1
ppubaanimz(emlneqsplz) = vlbuthiklx zoohxaunmb (jxuxuvkquv )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free